Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279890 · ClinicalTrials.gov registry record · Phase 1
Topical Agent for Treatment of Red Skin
A Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00279890: Completed Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks, sponsored by Mayo Clinic.
NCT00279890 is a Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00279890, a Phase 1 study of Rosacea and Bilaterally Symmetric Red Skin on Cheeks, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety
Conditions Studied
Interventions
- DRUG Topical SR-01
Study Locations (1)
Arizona
- Mayo Clinic - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
What the finished NCT00279890 record still lists
NCT00279890 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 242-participant average among 23 other Rosacea trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Topical SR-01 is the first listed.
NCT00279890 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT00279890 about?
NCT00279890 is a clinical study titled "Topical Agent for Treatment of Red Skin". SR-01 may reduce facial redness. it is a topically applied product. The agent will be applied to local skin areas of subjects with red facial skin to assess affect, and then applied to the whole face to assess efficacy and safety
What is the current status of trial NCT00279890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-07. Estimated completion is 2007-01.
What conditions does trial NCT00279890 study?
This clinical trial studies the following conditions: Rosacea, Bilaterally Symmetric Red Skin on Cheeks.
What interventions are being tested in trial NCT00279890?
The interventions under investigation include: Topical SR-01 (DRUG).
Who is sponsoring clinical trial NCT00279890?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00279890 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00279890's enrollment target sits among peer trials
20 23rd of 23 higher than 1 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
COMPLETED · Phase 1
-
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
COMPLETED · Phase 1
-
Timolol for the Treatment of Acne and Rosacea
COMPLETED · Phase 1
-
Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea
COMPLETED · Phase 1
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia